Several clinical trials of LGX818, either alone or in combinations with the MEK inhibitor MEK162, are being run. As a result of a successful Phase Ib/II trials, Phase III trials are currently being initiated.
Encorafenib
Sorafenib
Regorafenib
Tucatinib
Capmatinib
Afatinib
Neratinib
Lapatinib